Summary of Product Characteristics Updated 17-Nov-2023 | Neuraxpharm UK Ltd
Methocarbamol 1500 mg film-coated tablets
Each film-coated tablet contains 1500 mg methocarbamol.
Excipients with known effect
Each film-coated tablet contains 47.10 mg lactose (as monohydrate).
For the full list of excipients, see section 6.1.
Film-coated tablet
White, oblong biconvex film-coated tablets with a score line on one side.
Size: 23 mm ± 1.15mm x 10 mm ± 0.5 mm.
The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.
Symptomatic treatment of painful muscular tension, especially in the lower back (lumbago).
Methocarbamol is indicated in adults.
Posology
Adults
The recommended dose for adults is 1500 mg methocarbamol 3 times a day.
At the beginning of the treatment a dose of 1500 mg methocarbamol 4 times a day is recommended.
In severe cases up to 7500 mg methocarbamol can be taken each day.
The duration of treatment depends on the symptoms of muscle tension but should not exceed 30 days.
Paediatric population
The safety and efficacy of Methocarbamol in children and adolescents have not been established.
Elderly patients
Half the maximum dose or less may be sufficient to produce a therapeutic response.
Patients with hepatic impairment
In patients with chronic hepatic disease the elimination half-life may be prolonged. Therefore, consideration should be given to increasing the dose interval.
Method of administration
Methocarbamol is for oral use.
The film-coated tablets should be taken with sufficient water.
- Hypersensitivity to the active substance, or to any of the excipients listed in section 6.1.
- Comatose or pre-comatose states
- Disorders of the central nervous system (CNS)
- Myasthenia gravis
- Epilepsy
Methocarbamol should be used with caution in patients with impaired renal and/or hepatic function.
Methocarbamol tablets contain lactose
Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Methocarbamol tablets contain sodium
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'.
Interference with laboratory tests
Methocarbamol may cause colour interference in screening tests for hydroxyindoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA).
The concomitant administration of methocarbamol and centrally acting medicinal products such as barbiturates, opioids and appetite suppressants may potentiate the effect of these products.
Using methocarbamol together with alcohol may potentiate the effect of the medicinal product.
The effect of anticholinergics, such as atropine and other psychotropic medicinal products, may be increased by methocarbamol.
Consumption of alcohol during methocarbamol treatment may lead to an increased effect.
Methocarbamol may inhibit the effect of pyridostigmine bromide. Therefore, methocarbamol must not be taken by patients with myasthenia gravis, especially those who are being treated with pyridostigmine.
Pregnancy
There is no experience in the use of methocarbamol during pregnancy. Data from animal studies concerning effects on pregnancy, embryonic/foetal development, parturition and post- natal development are not available (see section 5.3). The potential risk to humans is not known. Methocarbamol should therefore not be used during pregnancy.
Breast-feeding
It is not known whether methocarbamol and/or its metabolites pass into human breast milk. Methocarbamol and/or its metabolites are excreted into the milk of lactating dogs. Therefore, methocarbamol should not be used during breast-feeding.
Fertility
No data are available concerning methocarbamol on human fertility.
Methocarbamol has moderate influence on the ability to drive and use machines as it may cause dizziness or drowsiness – especially if other medicinal products capable of causing drowsiness are also being taken.
Patients should be instructed that if dizziness or drowsiness occurs, these activities should be avoided.
The following undesirable effects were reported in connection with the use of methocarbamol.
Frequency data for adverse reactions are based on the following categories (where it has been possible to obtain frequency data from the literature):
| Very common | ≥ 1/10 |
| Common | ≥ 1/100 to < 1/10 |
| Uncommon | ≥ 1/1,000 to < 1/100 |
| Rare | ≥ 1/10,000 to < 1/1,000 |
| Very rare | < 1/10,000 |
| Not known | the frequency cannot be estimated from the available data |
The following adverse reactions have been reported with the use of methocarbamol:
| System organ class | Frequency according to MedDRA convention | ||
| Rare | Very rare | Not known | |
| Infections and infestations | Conjunctivitis | ||
| Immune system disorders | Anaphylactic reaction | ||
| Metabolism and nutrition disorders | Decreased appetite | ||
| Psychiatric disorders | Restlessness, anxiety, confusional state | ||
| Nervous system disorders | Headache, dizziness, metallic taste | Syncope, nystagmus, giddiness, tremor, seizure | Somnolence, coordination disturbance |
| Eye disorders | Visual impairment, diplopia | ||
| Cardiac disorders | Bradycardia | ||
| Vascular disorders | Hypotension | Hot flush | |
| Respiratory, thoracic and mediastinal disorders | Nasal congestion | ||
| Gastrointestinal disorders | nausea, vomiting | ||
| Skin and subcutaneous tissue disorders | Angioedema, rash, pruritus, urticaria | ||
| General disorders and administration site conditions | Pyrexia | ||
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Limited information is available on the acute toxicity of methocarbamol. Overdose of methocarbamol is frequently in conjunction with alcohol or other CNS depressants and includes the following symptoms: nausea, drowsiness, blurred vision, hypotension, seizures and coma.
After oral intake of 22.5 to 50 g methocarbamol with suicidal intent, two patients experienced drowsiness, but recovered completely within 24 hours.
In the literature, 3 fatal cases have been reported after methocarbamol was ingested with large quantities of alcohol (2 cases) or opiates (1 case) with suicidal intent.
Management of overdose includes gastric lavage symptomatic therapy and monitoring of vital functions. The usefulness of haemodialysis in managing overdose has not been established.
Pharmacotherapeutic group: muscle relaxants, centrally acting agents, carbamic acid esters
ATC code: M03BA03
Mechanism of action
Methocarbamol is a centrally acting muscle relaxant.
Pharmacodynamic effects
It exerts its myorelaxant effect by inhibiting the polysynaptic reflexes in the spinal cord and subcortical centres.
Clinical efficacy and safety
The physiological tonus and contractility of the skeletal muscles and the motility of the smooth muscles are not impaired by methocarbamol at therapeutic doses and there is no effect on the motor endplate.
Absorption
After oral administration, methocarbamol will be absorbed quickly and completely. The active substance is already detectable in the blood 10 minutes after ingestion and the peak blood concentration is reached after 30 - 60 minutes.
Distribution
The plasma half-life of methocarbamol is approximately 2 hours.
Biotransformation and elimination
Methocarbamol and its two main metabolites bind to glucuronic and sulphuric acid and are almost exclusively excreted via the kidneys. Approximately half of the administered dose is excreted through the urine within 4 hours, with only a small part being in the form of unchanged methocarbamol.
Renally impaired
The clearance of methocarbamol in renally-impaired patients on maintenance haemodialysis was reduced about 40% compared to a normal population, although the mean elimination half-life in these two groups was similar (1.2 versus 1.1 hours, respectively).
Hepatically impaired
In patients with cirrhosis secondary to alcohol abuse, the mean total clearance of methocarbamol was reduced approximately 70% compared to a normal population (11.9 L/hr), and the mean elimination half-life was extended to approximately 3.4 hours. The fraction of methocarbamol bound to plasma proteins was decreased to approximately 40 to 45% compared to 46 to 50% in an age and weight- matched normal population.
The acute toxicity of methocarbamol is comparatively low. Signs of intoxication in animal studies include ataxia, catalepsy, convulsions and coma.
Studies on chronic toxicity and on reproductive toxicity have not been performed.
In vitro and in vivo genetic toxicology studies with methocarbamol did not provide evidence of a mutagenic potential.
Long-term studies to investigate the carcinogenic potential have not been conducted.
Tablet core:
Lactose monohydrate,
Sodium croscarmellose,
Sodium laurilsulfate,
Povidone,
Anhydrous colloidal silica,
Magnesium stearate.
Film-coating:
Poly(vinylalcohol),
Titanium dioxide (E171),
Talc,
Macrogol 3350,
Not applicable.
PVC/aluminium blister packs:
3 years
ACLAR/aluminium blister packs:
3 years
PVC/aluminium blister packs:
The blister packs should not be stored above 30° C.
ACLAR/aluminium blister packs:
No special storage conditions are required for this medicinal product.
PVC/aluminium blister packs containing 100 or 100 (2 packs of 50) film-coated tablets.
ACLAR/aluminium blister packs containing 100 or 100 (2 packs of 50) film-coated tablets.
Not all pack sizes may be marketed.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
Neuraxpharm UK Limited
Unit 12 Farnborough Business Centre
Eelmoor Road
Farnborough
Hampshire GU14 7XA
United Kingdom
PL 49718/0056
02/03/2021
09/11/2023
Neuraxpharm UK Ltd, Suite 2, Arlington Flex, Third Floor, Building 1420, Arlington Business Park, Theale, Reading, Berkshire, RG7 4SA, UK
